COVID-19 and Antimicrobial Resistance: Parallel and Interacting Health Emergencies

Robby Nieuwlaat, Lawrence Mbuagbaw, Dominik Mertz, Lori Burrows, Dawn M. E. Bowdish, Lorenzo Moja, Gerry D. Wright, Holger J. Schünemann

Robby Nieuwlaat: Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton (ON), Canada

Lawrence Mbuagbaw: Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton (ON), Canada

Dominik Mert: Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster University, Hamilton (ON), Canada

Lori Burrows: Department of Pathology and Biomedical Sciences, McMaster University, Hamilton (ON), Canada

Dawn Bowdish: Department of Pathology and Molecular Medicine, McMaster University, Hamilton (ON), Canada

Lorenzo Moja: Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland

Gerry Wright: Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton (ON), Canada

Holger J. Schunemann: Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton (ON), Canada

Corresponding author:

Robby Nieuwlaat

Email: nieuwlr@mcmaster.ca
Summary:

1. The COVID-19 pandemic and antimicrobial resistance are parallel and interacting health emergencies with opportunity for mutual learning
2. Researchers should now start collecting data to measure the impact of current COVID-19 policies and programs on antimicrobial resistance

Abstract

The COVID-19 pandemic and antimicrobial resistance are parallel and interacting health emergencies with opportunity for mutual learning. As their measures and consequences are comparable, the COVID-19 pandemic helps to illustrate the potential long-term impact of AMR, which is less acute but not less crucial. They may also impact each other as there is a push to resort to existing antimicrobials in critically ill COVID-19 patients in the absence of specific treatments, while attempts to manage the spread of COVID-19 may also lead to a slow down AMR. Understanding how COVID-19 affects AMR trends and what we can expect if these remain the same or worsen, will help us plan next steps to tackle AMR. Researchers should now start collecting data to measure the impact of current COVID-19 policies and programs on AMR.

Keywords: COVID-19, SARS-CoV-2, antimicrobial resistance, antibiotic resistance
Introduction

The COVID-19 pandemic has been spreading swiftly, absorbing enormous resources from public health and healthcare systems to limit its damage. This emergency has vast health consequences, not only in terms of the direct health impact on COVID-19 patients, but also indirectly on the global economy and societies across the globe.[1,2] Most countries are activating all possible countermeasures towards containing and treating COVID-19.[3] Inevitably, other health care issues need to adjust and may temporarily receive less attention.[4,5] Antimicrobial resistance (AMR) is an emergency that should not fall off the radar.[6] Certain actions to alleviate COVID-19 suffering might represent a rapid and far-reaching risk to AMR, a phenomenon projected to afflict our society well over the COVID-19 crisis.

Two health emergencies

AMR exists because micro-organisms who are resistant to antimicrobial agents survive and replicate. The overuse and inappropriate use of antibiotics in humans and animals, and their contamination of the environment, are substantial contributors to AMR. In the United States alone, each year at least 2.8 million people become infected with bacteria that are resistant to antibiotics and at least 35,000 people (1.3%) die as a result.[7] It was estimated in 2014 that globally, if there was no change in the increasing trend and resistance grows apace, AMR could result in as many as 10 million deaths in 2050 and have a cumulative loss in economic output of at least 60 trillion USD by 2050.[8] Whether or not these estimates are accurate, the significant negative trends in damage to the economy and population health are certain.[9]

AMR has recognized as a pervasive public health threat national and international organizations for decades, with gradually increasing perceived urgency, modest dedicated funding, and international treaties and initiatives.[10] Now, the COVID-19 pandemic has further complicated the era of AMR. As of April 30 (2020) there have been over 6 million cases and over 300,000 deaths.[2] Having recently become a WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations with a focus on AMR, we believe the COVID-19 pandemic helps to illustrate the potential impact of AMR (Table 1).[11] Alongside, it is sensible to discuss the potential effects of the COVID-19 pandemic on AMR and the opportunities that may arise.

Parallels

COVID-19 is a new infectious disease caused by SARS-CoV-2 requiring swift knowledge creation and innovation, and its outbreak has been declared a global pandemic by the World Health Organization (WHO) on March 11, 2020. AMR is also pandemic in nature, but in contrast a gradual but implacable process affecting multiple microorganisms for which we have some established knowledge. Despite these differences, the required behaviour changes that have been implemented to deal with the COVID-19 pandemic would also benefit AMR that faces a similar path. Infection protection and control measures such as handwashing, physical distancing, quarantining, and travel restrictions can be seen as an effective adaptation to reduce the health risks of AMR.[12] In addition, the healthcare system will be seriously tested, for example when there are insufficient prophylactic antimicrobials for invasive procedures, and social inequalities will be amplified, for example when certain sociodemographic
groups are at increased risk of infection.[12] The occurrence of infections due to resistant pathogens can be significantly mitigated by evidence-based antimicrobial stewardship across all sectors (agriculture, veterinary and human medicine). Although this buys us time, AMR will not be restrained if we do not also develop new vaccines, drugs and rapid tests that are scalable, as is the mandate for COVID-19. The deaths from COVID-19 may overtake the deaths from AMR for 2020, but the estimated annual number of deaths from AMR of 10 million by 2050 may well be higher than the toll from the entire COVID-19 pandemic (currently just crossed the 200,000 mark worldwide). A potentially high use of antimicrobials in COVID-19 patients may also shift gains in short-term COVID-19 mortality to an increase in long-term AMR mortality. Those deaths and impact on our social and health systems will likely have lasting negative effects on the economy as COVID-19 will, but over a much longer period of time. Similarly, the current strategies to combat COVID-19 using urgent action, international collaboration, and development of new treatments, vaccines and rapid tests are required for AMR. These approaches were already underway, but at a much slower pace and smaller scale, considering, for example, the lack of investment in developing new antimicrobials and vaccines.[13] In other words, the measures and consequences of both COVID-19 and AMR are comparable, although the urgency of action is largely in favor of COVID-19. The response to the high-speed pandemic of COVID-19 shows that initiatives tackling AMR could be done faster. And vice versa, the response to COVID-19 needs to be informed by lessons learned from studying the slow-motion problem of AMR.

Interactions

The two emergencies are also intertwined. There is a push to resort to existing antimicrobials in critically ill COVID-19 patients, in the absence of specific treatments when supportive care alone is not enough. As with other viral infections, severely ill patients are at increased risk of secondary infections that can be fatal and require additional treatment.[14] These issues are further complicated by the fact that the most prevalent symptoms of SARS-CoV-2, cough and fever, are independent factors associated with overuse of antibiotics in hospitals and communities.[15] One has to keep in mind that the role of macrolides, quinolones and other antimicrobials such as chloroquine and its derivative has not yet been proven, and can be harmful.[16] The bottom line is that to identify the most effective medicine to improve outcomes for COVID-19 patients, multiple antimicrobials are being tested in formal research settings (randomized trials) as well as in ad hoc studies, and this may further exacerbate rates of AMR. As of June 3 in ClinicalTrials.gov, 211 COVID-19 records contained ‘hydroxychloroquine’ and 93 contained ‘azithromycin’, a common antibiotic for the treatment of bacterial infections. Until the findings of these studies are released, use of antimicrobials might be inspired by the principle of parsimony recommended by WHO.[17]

Attempts to manage the spread of COVID-19 may also lead to a lower use of antimicrobials and slow down AMR, particularly if the pandemic is going to last over a long period.[18] Behavioural interventions, including physical barriers, to prevent the spread of SARS-CoV-2 will likely decrease the spread of other infections, and thus the use of antimicrobials. Furthermore, there are signals that patients with other health issues, acute or less urgent, are reluctant to seek care, which may also be true for patients with other types of infections.[19,20] Finally, shortages in certain antimicrobials due to
stress on the global supply chain could lead to a further reduction in their use.\[21\] In short, COVID-19 and AMR have multiple potential interactions, but at present it is uncertain how they will unfold.

What to do?

The COVID-19 pandemic currently requires our full commitment to limit its harm. We expect that it will serve as an illustration to recognize the potential effects of AMR, which is less acute but not less crucial, and that there are lessons to be learnt by carefully examining the parallels and interactions between COVID-19 and AMR. Understanding how COVID-19 affects AMR trends and what we can expect if these remain the same or worsen, will help us plan next steps to tackle AMR. Researchers should now start collecting data to measure the impact of current COVID-19 policies and programs on AMR.
**Funding**

This work was not supported by funding.

**Conflicts of Interest**

Robby Nieuwlaat: No conflict
Lawrence Mbuagbaw: No conflict
Dominik Mertz: No conflict
Lori Burrows: No conflict
Dawn M. E. Bowdish: No conflict
Lorenzo Moja: No conflict
Gerry D. Wright: No conflict
Holger J. Schünemann: No conflict
References

1. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. *J Am Coll Cardiol.* 2020 Mar 18. DOI: 10.1016/j.jacc.2020.03.031.

2. World Health Organization. Coronavirus disease (COVID-19) outbreak situation - Dashboard [https://covid19.who.int/](https://covid19.who.int/) (April 30, 2020).

3. Hartley DM, Perencevich EN. Public Health Interventions for COVID-19: Emerging Evidence and Implications for an Evolving Public Health Crisis. *JAMA.* 2020 Apr 10. DOI: 10.1001/jama.2020.5910.

4. Blandino G. Cancer at the time of the COVID-19 hurricane. *Journal of Experimental & Clinical Cancer Research.* 2020; (In press). DOI: 10.1186/s13046-020-01575-1.

5. Shah PB, Welt FGP, Mahmud E, Phillips A, Kleiman NS, Young MN, et al. Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement. *Catheter Cardiovasc Interv.* 2020 Apr 6. DOI: 10.1002/ccd.28910.

6. Antimicrobial resistance in the age of COVID-19. *Nat Microbiol* 2020; 5(6):779.

7. CDC. Antibiotic resistance threats in the United States. Atlanta (GA), USA: CDC; 2019.

8. The Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. The Review on Antimicrobial Resistance; 2016.

9. de Kraker ME, Stewardson AJ, Harbarth S. Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? *PLoS Med* 2016; 13(11):e1002184.

10. Podolsky SH. The evolving response to antibiotic resistance (1945–2018). *Palgrave Commun.* 2018; 4(124). DOI: 10.1057/s41599-018-0181-x.

11. National Collaborating Centre for Infectious Diseases. 2020 [https://nccid.ca/](https://nccid.ca/) (April 30, 2020).

12. Council of Canadian Academies. When Antibiotics Fail. Ottawa (ON): Council of Canadian Academies; 2019. Report No.: ISBN: 978-1-926522-75-3.

13. IACG. No time to wait: securing the future from drug-resistant infections. Report to the secretary-general of the United Nations. IACG; 2019.

14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395(10229):1054-62.

15. PHAC. Handle With Care: Preserving Antibiotics Now and Into the Future. Chief Public Health Officer of Canada’s 2019 Spotlight Report. Ottawa: PHAC; 2019.

16. Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). *Crit Care Med.* 2020 Mar 27. DOI: 10.1097/CCM.0000000000004363.

17. Sharland M, Gandra S, Huttner B, Moja L, Pulcini C, Zeng M, et al. Encouraging AWARe-ness and discouraging inappropriate antibiotic use—the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. *Lancet Infect Dis* 2019; 19(12):1278-80.

18. Rawson TM, Moore LSP, Castro-Sanchez E, Charani E, Davies F, Satta G, et al. COVID-19 and the potential long-term impact on antimicrobial resistance. *J Antimicrob Chemother* 2020;

19. De Filippo O, D’Ascenzo F, Angelini F, Bocchino PP, Conrotto F, Saglietto A, et al. Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy. *N Engl J Med* 2020;

20. Lazzerini M, Barbi E, Apicella A, Marchetti F, Cardinale F, Trobia G. Delayed access or provision of care in Italy resulting from fear of COVID-19. *Lancet Child Adolesc Health.* 2020 Apr 9 PMC7146704]. DOI: 10.1016/S2352-4642(20)30108-5.
21. Centers for Disease Control and Prevention. Azithromycin Shortage 2020 [updated April 15, 2020. https://www.cdc.gov/std/treatment/drugnotices/azithromycin-2020.htm (April 30, 2020).
Table 1. Comparison of COVID-19 and AMR

| Characteristics                          | COVID-19                                   | AMR                           |
|------------------------------------------|--------------------------------------------|-------------------------------|
| Number affected worldwide                | 6.28 million* (annually: unknown)          | 64.5 million annually^        |
| Knowledge of problem                     | Developing                                 | Established                   |
| Spread                                   | Fast                                       | Gradual                       |
| Mechanism                                | New transfer from non-human host           | Natural selection in humans, animals, and environment |
| **Behaviour change required**            |                                            |                               |
| Handwashing                              | Continuously needed                        | Continuously needed           |
| Physical distancing                      | Urgent, possibly recurrent                 | Probably recurrent            |
| Travel restrictions                      | Urgent, possibly recurrent                 | Probably recurrent            |
| Quarantine                               | Confirmed and suspected cases              | Confirmed and suspected cases |
| **Impacts**                              |                                            |                               |
| Mortality worldwide                      | 379,000* (annually: unknown)               | 812,000 annually^             |
| Economic impact                          | Unknown                                    | 400 billion USD^               |
| Health inequity                          | Increased                                  | Increased                     |
| **Management Needs**                     |                                            |                               |
| Vaccine                                  | In development                             | Not available for resistant microbes |
| Augmented testing                        | Real-time picture of spread                | Surveillance of problem       |
| Rapid diagnostics                        | In development                             | Some useful tests (procalcitonin, CRP) |
| New drugs                                | In development                             | Few in development             |
| Stewardship                              | In time                                    | Continuously & internationally |
December 2019 to June 3, 2020 – World Health Organization. Extrapolated based on the US having 2.8 million annually, and 4.31% of global population. # Extrapolated based on the US having 35,000 annually, and 4.31% of the global population. † 0.5% of 80 trillion GWP.

WHO = World Health Organization; CDC = Centers for Disease Control and Prevention; HAI = hospital-acquired infections; QoL = quality of life; USD = US Dollar; GWP = Gross world product; CRP = C-reactive protein